Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression

Angiogenesis. 2010 Dec;13(4):327-35. doi: 10.1007/s10456-010-9189-6. Epub 2010 Sep 25.

Abstract

Background: infantile hemangioma (IH) is a most common tumor of infancy. Using infantile hemangioma-derived stem cells (HemSCs), we recently demonstrated that corticosteroids suppress the expression of VEGF-A, monocyte chemoattractant protein-1 (MCP-1), urokinase plasminogen activator receptor (uPAR), and interleukin-6 (IL-6); each of these are known targets of the transcription factor nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB). In the present study, we examined the expression of these NF-κB target genes in IH tissue specimens and the effect of NF-κB regulation on the expression of pro-angiogenic cytokines, and in particular VEGF-A, in HemSCs.

Materials and methods: RNA extracted from IH tissue and hemangioma-derived stem cells (HemSCs) was used to analyze NF-κB target gene expression by reverse transcription-quantitative PCR (RT-qPCR). The effects of NF-κB blockade were examined in HemSCs. Immunostaining, immunoblotting and ELISA were used to assess protein expression.

Results: MCP-1, uPAR, and IL-6 were found to be differentially expressed in proliferating versus involuting IH. Corticosteroids suppressed NF-κB activity of HemSCs. Velcade (Bortezomib), a proteosome inhibitor that can indirectly inhibit NF-κB, impaired HemSCs viability and expression of pro-angiogenic factors. Furthermore, specific inhibition of NF-κB resulted in suppression of VEGF-A.

Conclusions: we demonstrate expression of NF-κB target genes in proliferating IH. In addition, we show that the expression of several pro-angiogenic factors in HemSCs, and in particular VEGF-A, is regulated by NF-B activity.

Publication types

  • Evaluation Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Boronic Acids / pharmacology
  • Bortezomib
  • Cell Proliferation / drug effects
  • Child
  • Child, Preschool
  • Dexamethasone / pharmacology
  • Female
  • Gene Expression Regulation, Neoplastic / drug effects
  • Hemangioma, Capillary / congenital
  • Hemangioma, Capillary / drug therapy
  • Hemangioma, Capillary / genetics
  • Hemangioma, Capillary / metabolism
  • Hemangioma, Capillary / pathology
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Molecular Targeted Therapy / methods
  • NF-kappa B / antagonists & inhibitors*
  • NF-kappa B / genetics
  • NF-kappa B / metabolism
  • Neoplastic Stem Cells / drug effects
  • Neoplastic Stem Cells / metabolism*
  • Neoplastic Stem Cells / pathology
  • Neoplastic Syndromes, Hereditary
  • Pyrazines / pharmacology
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / genetics
  • Skin Neoplasms / metabolism
  • Skin Neoplasms / pathology
  • Vascular Endothelial Growth Factor A / genetics*
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • NF-kappa B
  • Pyrazines
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bortezomib
  • Dexamethasone

Supplementary concepts

  • Hemangioma, capillary infantile